EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative products based on the NexACT® drug delivery technology, today confirmed that eight presentations on NM100060, a topical treatment for onychomycosis (nail fungus) licensed to Novartis, will be made at two conferences in July and September 2008, as follows:
